NicOx conserves funds following naproxcinod disappointment
This article was originally published in Scrip
In light of the recent setback with its lead candidate naproxcinod, NicOx is "reviewing all aspects of its cost base to ensure careful conservation of its funds" and as a result has decided to delay the start of a Phase II study of its next in-house product candidate NCX 6560 until clarification of naproxcinod's regulatory position.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.